Per-procedural Concentration of Direct Oral Anticoagulants — CORIDA  

Per-procedural Concentrations of Oral Anticoagulants Clinical Trial

Status Completed

Clinical Trial Summary

Background: Peri-procedural management of direct oral anticoagulants (DOAC) is challenging. The optimal duration of pre-procedural discontinuation that guarantees a minimal DOAC concentration ([DOAC]) at surgery is unknown. The usual 48-hour discontinuation might not be sufficient for all patients.

Objectives: To investigate the factors associated with per-procedural [DOAC]. To test the hypothesis that a 48-hour DOAC discontinuation is not sufficient to ensure a minimal perprocedural [DOAC], defined as [DOAC] < 30 ng/mL.

Methods: Patients treated with DOAC, and requiring any invasive procedure will be included in this multicentre, prospective, observational study. [DOAC], will be measured during invasive procedure.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Per-procedural Concentrations of Oral Anticoagulants

• NCT number: NCT02643992
• Study type: Observational
• Source: Fondation Ophtalmologique Adolphe de Rothschild
• Status: Completed
• Phase: N/A
• Start date: June 2013
• Completion date: January 2016